# AELIN THERAPEUTICS

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aelin-therapeutics

- Industry: Biotechnology
- Headquarters: Leuven, Belgium
- Website: www.aelintx.com/
- Total disclosed funding: $32M
- Latest round: Series A (Dec 11, 2017)
- Investors on record: 5

## About

Based in Belgium, and founded in 2017 by co-founders Frederic Rousseau, and Joost Schymkowitz, Aelin Therapeutics operates as a biotherapeutics company that specializes in drug discovery through its Pept-in technology platform. In December 2017, the firm raised EUR 27 million in series A funding led by Boehringer Ingelheim Venture, Fund+, LSPvc, Novartis Venture Fund, and PMV. In June 2023, AELIN THERAPEUTICS filed for chapter 11 bankruptcy protection.

Aelin's core offering is the Pept-in technology platform designed to knock down the function of critical oncoproteins and induce tumor cell death, providing a complementary strategy to existing cancer treatments. The platform interacts with intracellular targets in mammals, bacteria, and viruses, thus broadening the scope of potential therapeutic solutions.

## Funding rounds

- Series A, Dec 11, 2017, $32M — Novartis Venture Fund, EQT Life Sciences, PMV, Boehringer Ingelheim Venture, Fund+

## Investors

- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A
- PMV (https://capitalatlas.ai/funds/pmv) — Series A
- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Series A
- Fund+ (https://capitalatlas.ai/funds/fund) — Series A